Fragile X syndrome: From protein function to therapy
The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Abstract
Fragile X syndrome (FXS) is the leading monogenic cause of intellectual disability and autism. The FMR1 gene contains a CGG repeat present in the 5′‐untranslated region which can be unstable upon transmission to the next generation. The repeat is up to 55 CGGs long in the normal population. In patients with fragile X syndrome (FXS), a repeat length exceeding 200 CGGs generally leads to methylation of the repeat and the promoter region, which is accompanied by silencing of the FMR1 gene. The disease is a result of lack of expression of the fragile X mental retardation protein leading to severe symptoms, including intellectual disability, hyperactivity, and autistic‐like behavior. The FMR1 protein (FMRP) has a number of functions. The translational dysregulation of a subset of mRNAs targeted by FMRP is probably the major contribution to FXS. FMRP is also involved in mRNA transport to synapses where protein synthesis occurs. For some FMRP‐bound mRNAs, FMRP is a direct modulator of mRNA stability either by sustaining or preventing mRNA decay. Increased knowledge about the role of FMRP has led to the identification of potential treatments for fragile X syndrome that were often tested first in the different animal models. This review gives an overview about the present knowledge of the function of FMRP and the therapeutic strategies in mouse and man. © 2013 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Verkerk, A. J. M. H., Pieretti, M., Sutcliffe, J. S., Fu, Y.-H., Kuhl, D. P. A., Pizzuti, A., Reiner, O., Richards, S., Victoria, M. F., Zhang, F., et al. (1991) · Cell · doi:10.1016/0092-8674(91)90397-h · Cited by 3,481
Self-citationFu, Y.-H., Kuhl, D. P. A., Pizzuti, A., Pieretti, M., Sutcliffe, J. S., Richards, S., Verkert, A. J. M. H., Holden, J. J. A., Fenwick, R. G., Warren, S. T., et al. (1991) · Cell · doi:10.1016/0092-8674(91)90283-5 · Cited by 2,080 · cited 2×
“The risk of transition is dependent on the size of the premutation, which accounts for the Sherman paradox [Fu et al., 1991].”
BackgroundSelf-citationFMRP Stalls Ribosomal Translocation on mRNAs Linked to Synaptic Function and Autism
Darnell, J. C., Van Driesche, S. J., Zhang, C., Hung, K. Y. S., Mele, A., Fraser, C. E., Stone, E. F., Chen, C., Fak, J. J., Chi, S. W., et al. (2011) · Cell · doi:10.1016/j.cell.2011.06.013 · Cited by 2,072 · cited 2×
“Last but not least, over the last 10 years, a plethora of putative FMRP targetsmRNAshave been identified inneuronal [Brownet al., 2001; Chen et al., 2003; Miyashiro et al., 2003; Zalfa et al., 2003, 2007; Muddashetty et al., 2007; Darnell et al., 2011] (Fig.”
BackgroundThe mGluR theory of fragile X mental retardation
Bear, M. F., Huber, K. M., & Warren, S. T. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.04.009 · Cited by 1,580 · cited 1×
“, 2007; Ronesi and Huber, 2008] and has settled the bases to describe the “mGluR theory” [Bear et al., 2004].”
BackgroundInstability of a 550-Base Pair DNA Segment and Abnormal Methylation in Fragile X Syndrome
Oberlé, I., Rousseau, F., Heitz, D., Kretz, C., Devys, D., Hanauer, A., Boué, J., Bertheas, M. F., & Mandel, J. L. (1991) · Science · doi:10.1126/science.252.5009.1097 · Cited by 1,499
Altered synaptic plasticity in a mouse model of fragile X mental retardation
Huber, K. M., Gallagher, S. M., Warren, S. T., & Bear, M. F. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122205699 · Cited by 1,349 · cited 2×
“This effect on LTD is likely due to deregulated local protein synthesis [Huber et al., 2002; Lu et al., 2004; Nosyreva and Huber, 2006; Muddashetty et al., 2007; Zalfa et al., 2007; Ronesi and Huber, 2008] and has settled the bases to describe the “mGluR theory” [Bear et al.”
BackgroundRapid Spine Delivery and Redistribution of AMPA Receptors After Synaptic NMDA Receptor Activation
Shi, S.-H., Hayashi, Y., Petralia, R. S., Zaman, S. H., Wenthold, R. J., Svoboda, K., & Malinow, R. (1999) · Science · doi:10.1126/science.284.5421.1811 · Cited by 1,276 · cited 1×
“Local protein synthesis is required for long-lasting formsof synaptic plasticity that underlie consolidation of long-term memories [Flavell and Greenberg, 2008] and is orchestrated by the action of glutamate receptors; the ionotropic receptors N-methyl-D-aspartate (NMDAR), the alpha-amino-3-hydroxy-5-methyl-4-isoxazol…”
BackgroundBrown, V., Jin, P., Ceman, S., Darnell, J. C., O'Donnell, W. T., Tenenbaum, S. A., Jin, X., Feng, Y., Wilkinson, K. D., Keene, J. D., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00568-2 · Cited by 1,109
Anderson, P., & Kedersha, N. (2006) · The Journal of Cell Biology · doi:10.1083/jcb.200512082 · Cited by 984 · cited 1×
“FMRP has also been detected in P bodies (PB) and stress granules (SG) containing translationally silent pre-initiation complexes [Anderson and Kedersha, 2006] further suggesting its role in mRNA metabolism.”
BackgroundCorrection of Fragile X Syndrome in Mice
Dölen, G., Osterweil, E., Rao, B. S. S., Smith, G. B., Auerbach, B. D., Chattarji, S., & Bear, M. F. (2007) · Neuron · doi:10.1016/j.neuron.2007.12.001 · Cited by 979
Flavell, S. W., & Greenberg, M. E. (2008) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.31.060407.125631 · Cited by 832
Regulation of Synaptic Structure and Function by FMRP-Associated MicroRNAs miR-125b and miR-132
Edbauer, D., Neilson, J. R., Foster, K. A., Wang, C.-F., Seeburg, D. P., Batterton, M. N., Tada, T., Dolan, B. M., Sharp, P. A., & Sheng, M. (2010) · Neuron · doi:10.1016/j.neuron.2010.01.005 · Cited by 735 · cited 1×
“…RNAs, including the brain cytoplasmic RNA BC1/BC200 [Ashley et al., 1993; Siomi et al., 1993; O’Donnell and Warren, 2002; Zalfa et al., 2005; Johnson et al., 2006;Napoli et al., 2008] andmicroRNAs [Edbauer et al., 2010; Gessert et al., 2010; Muddashetty and Bassell, 2009; Tian et al., 2013].”
FMRP targets distinct mRNA sequence elements to regulate protein expression
Ascano, M., Mukherjee, N., Bandaru, P., Miller, J. B., Nusbaum, J. D., Corcoran, D. L., Langlois, C., Munschauer, M., Dewell, S., Hafner, M., et al. (2012) · Nature · doi:10.1038/nature11737 · Cited by 701
DNA methylation represses FMR-1 transcription in fragile X syndrome
Sutcliffe, J. S., Nelson, D. L., Zhang, F., Pieretti, M., Caskey, C. T., Saxe, D., & Warren, S. T. (1992) · Human Molecular Genetics · doi:10.1093/hmg/1.6.397 · Cited by 680
Zalfa, F., Giorgi, M., Primerano, B., Moro, A., Di Penta, A., Reis, S., Oostra, B., & Bagni, C. (2003) · Cell · doi:10.1016/s0092-8674(03)00079-5 · Cited by 676 · cited 4×
“FMRP may repress translation during the initiation step [Siomi et al., 1996; Laggerbauer et al., 2001; Ishizuka et al., 2002; Zalfa et al., 2003; Monzo et al., 2006; Napoli et al., 2008; Papoulas et al., 2010] and/or elongation [Ceman et al., 2003; Khandjian et al., 2004; Stefani et al., 2004;…”
BackgroundInfluentialSelf-citationThe protein product of the fragile X gene, FMR1, has characteristics of an RNA-binding protein.
Siomi, H., Siomi, M. C., Nussbaum, R. L., & Dreyfuss, G. (1993) · Cell · doi:10.1016/0092-8674(93)90420-u · Cited by 641
Jacquemont, S., Curie, A., des Portes, V., Torrioli, M. G., Berry-Kravis, E., Hagerman, R. J., Ramos, F. J., Cornish, K., He, Y., Paulding, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001708 · Cited by 609 · cited 1×
“Use of the selectivemGluR5 antagonist AFQ056/Mavoglurantwas not associated with significant group treatment effect in a doubleblind, placebo-controlled two-period crossover study in 30 males with FXS aged 18–35 years [Jacquemont et al., 2011].”
MethodThe Fragile X Syndrome Protein Represses Activity-Dependent Translation through CYFIP1, a New 4E-BP
Napoli, I., Mercaldo, V., Boyl, P. P., Eleuteri, B., Zalfa, F., De Rubeis, S., Di Marino, D., Mohr, E., Massimi, M., Falconi, M., et al. (2008) · Cell · doi:10.1016/j.cell.2008.07.031 · Cited by 609
Self-citationA Drosophila fragile X protein interacts with components of RNAi and ribosomal proteins
Ishizuka, A., Siomi, M. C., & Siomi, H. (2002) · Genes & Development · doi:10.1101/gad.1022002 · Cited by 581
Evidence that fragile X mental retardation protein is a negative regulator of translation
Laggerbauer, B. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.4.329 · Cited by 571
Abnormal Development of Dendritic Spines in FMR1 Knock-Out Mice
Nimchinsky, E. A., Oberlander, A. M., & Svoboda, K. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-14-05139.2001 · Cited by 560 · cited 1×
“But most of the studies report an immature dendritic spine phenotype either in the cortex or thehippocampusofFmr1KOmice, comparedwith thewild-type (WT) littermate controls [Nimchinsky et al., 2001; Irwin et al., 2002; Galvez and Greenough, 2005; McKinney et al., 2005; Grossman et al., 2006; Bilousova et al., 2008; Cru…”
BackgroundDysregulation of mTOR signaling in fragile X syndrome
Sharma, A., Hoeffer, C. A., Takayasu, Y., Miyawaki, T., McBride, S. M., Klann, E., & Zukin, R. S. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.3696-09.2010 · Cited by 557
Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP
Yan, Q. J., Rammal, M., Tranfaglia, M., & Bauchwitz, R. P. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.06.004 · Cited by 521
Dictenberg, J. B., Swanger, S. A., Antar, L. N., Singer, R. H., & Bassell, G. J. (2008) · Developmental Cell · doi:10.1016/j.devcel.2008.04.003 · Cited by 511
RNA cargoes associating with FMRP reveal deficits in cellular functioning in Fmr1 null mice
Miyashiro, K. Y., Beckel-Mitchener, A., Purk, T. P., Becker, K. G., Barret, T., Liu, L., Carbonetto, S., Weiler, I. J., Greenough, W. T., & Eberwine, J. (2003) · Neuron · doi:10.1016/s0896-6273(03)00034-5 · Cited by 495
The translation of translational control by FMRP: therapeutic targets for FXS
Darnell, J. C., & Klann, E. (2013) · Nature Neuroscience · doi:10.1038/nn.3379 · Cited by 491 · cited 2×
“The translational dysregulation of a subset of mRNAs targeted by FMRP is probably themajor contribution to FXS [Bagni et al., 2012; Darnell and Klann, 2013].”
BackgroundChronic Pharmacological mGlu5 Inhibition Corrects Fragile X in Adult Mice
Michalon, A., Sidorov, M., Ballard, T. M., Ozmen, L., Spooren, W., Wettstein, J. G., Jaeschke, G., Bear, M. F., & Lindemann, L. (2012) · Neuron · doi:10.1016/j.neuron.2012.03.009 · Cited by 489
Hou, L., Antion, M. D., Hu, D., Spencer, C. M., Paylor, R., & Klann, E. (2006) · Neuron · doi:10.1016/j.neuron.2006.07.005 · Cited by 469
Bilousova, T. V., Dansie, L., Ngo, M., Aye, J., Charles, J. R., Ethell, D. W., & Ethell, I. M. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2008.061796 · Cited by 465
Muddashetty, R. S., Kelić, S., Gross, C., Xu, M., & Bassell, G. J. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.0937-07.2007 · Cited by 421
A pilot open label, single dose trial of fenobam in adults with fragile X syndrome
Berry-Kravis, E., Hessl, D., Coffey, S., Hervey, C., Schneider, A., Yuhas, J., Hutchison, J., Snape, M., Tranfaglia, M., Nguyen, D. V., et al. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2008.063701 · Cited by 411 · cited 1×
“antagonist fenobam showed clinical benefit including reductions in hyperactivity and anxiety [Berry-Kravis et al., 2009].”
BackgroundEberhart, D. (1996) · Human Molecular Genetics · doi:10.1093/hmg/5.8.1083 · Cited by 390
Osterweil, E. K., Krueger, D. D., Reinhold, K., & Bear, M. F. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.3888-10.2010 · Cited by 384 · cited 1×
“The HMG-CoA reductase inhibitor lovastatin can inhibit Ras-ERK1/2 signaling in hippocampal neurons [Li et al., 2005] and the ERK1/2 signaling pathway lies upstream of the excessive hippocampal protein synthesis in the Fmr1 KO mice [Osterweil et al., 2010].”
BackgroundSchenck, A., Bardoni, B., Moro, A., Bagni, C., & Mandel, J.-L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151231598 · Cited by 356
Self-citationAltered anxiety‐related and social behaviors in the Fmr1 knockout mouse model of fragile X syndrome
Spencer, C. M., Alekseyenko, O., Serysheva, E., Yuva‐Paylor, L. A., & Paylor, R. (2005) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2005.00123.x · Cited by 349
Characterization and localization of the FMR-1 gene product associated with fragile X syndrome
Verheij, C., Bakker, C. E., de Graaff, E., Keulemans, J., Willemsen, R., Verkerk, A. J. M. H., Galjaard, H., Reuser, A. J. J., Hoogeveen, A. T., & Oostra, B. A. (1993) · Nature · doi:10.1038/363722a0 · Cited by 343 · cited 1×
“As a consequence the gene is transcriptionally silenced and the geneproduct, the fragileX mental retardation protein (FMRP), is absent [Verheij et al., 1993].”
BackgroundSelf-citationBerry-Kravis, E. M., Hessl, D., Rathmell, B., Zarevics, P., Cherubini, M., Walton-Bowen, K., Mu, Y., Nguyen, D. V., Gonzalez-Heydrich, J., Wang, P. P., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004214 · Cited by 328
Phosphorylation influences the translation state of FMRP-associated polyribosomes
Ceman, S., O'Donnell, W. T., Reed, M., Patton, S., Pohl, J., & Warren, S. T. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg350 · Cited by 327 · cited 2×
“In parallel, FMRP has also been found to be highly phosphorylated when it co-sediments with polyribosomes whereas its dephosphorylation releases FMRP from polysomes allowing protein synthesis [Ceman et al., 2003].”
BackgroundFragile X syndrome: causes, diagnosis, mechanisms, and therapeutics
Bagni, C., Tassone, F., Neri, G., & Hagerman, R. (2012) · Journal of Clinical Investigation · doi:10.1172/jci63141 · Cited by 321
Self-citationDelayed Stabilization of Dendritic Spines in Fragile X Mice
Cruz-Martin, A., Crespo, M., & Portera-Cailliau, C. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.0577-10.2010 · Cited by 321 · cited 1×
“But most of the studies report an immature dendritic spine phenotype either in the cortex or thehippocampusofFmr1KOmice, comparedwith thewild-type (WT) littermate controls [Nimchinsky et al., 2001; Irwin et al., 2002; Galvez and Greenough, 2005; McKinney et al., 2005; Grossman et al., 2006; Bilousova et al., 2008; Cru…”
BackgroundDecreased expression of the GABAA receptor in fragile X syndrome
D'Hulst, C., De Geest, N., Reeve, S. P., Van Dam, D., De Deyn, P. P., Hassan, B. A., & Kooy, R. F. (2006) · Brain Research · doi:10.1016/j.brainres.2006.08.115 · Cited by 318 · cited 2×
“The eight GABA receptor subunits (a1,a3,a4,b1,b2, g1, g2, and d) were significantly reduced in cortex but not in cerebellum of Fmr1 KO mice [D’Hulst et al., 2006].”
BackgroundSynaptic regulation of protein synthesis and the fragile X protein
Greenough, W. T., Klintsova, A. Y., Irwin, S. A., Galvez, R., Bates, K. E., & Weiler, I. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141145998 · Cited by 317
Tsai, N.-P., Wilkerson, J. R., Guo, W., Maksimova, M. A., DeMartino, G. N., Cowan, C. W., & Huber, K. M. (2012) · Cell · doi:10.1016/j.cell.2012.11.040 · Cited by 316 · cited 1×
“FMRPexpressionandconsequently its functioncanbe regulatedby posttranslational modifications such as ubiquitination [Hou et al., 2006; Tsai et al., 2012] and/or phosphorylation [Ceman et al.”
BackgroundSchenck, A., Bardoni, B., Langmann, C., Harden, N., Mandel, J.-L., & Giangrande, A. (2003) · Neuron · doi:10.1016/s0896-6273(03)00354-4 · Cited by 316
Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice
de Vrij, F. M. S., Levenga, J., van der Linde, H. C., Koekkoek, S. K., De Zeeuw, C. I., Nelson, D. L., Oostra, B. A., & Willemsen, R. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.04.002 · Cited by 313
Self-citationHagerman, R. J. (2002) · doi:10.56021/9780801868436 · Cited by 299
Restivo, L., Ferrari, F., Passino, E., Sgobio, C., Bock, J., Oostra, B. A., Bagni, C., & Ammassari-Teule, M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504984102 · Cited by 299
Self-citationAudiogenic Seizures Susceptibility in Transgenic Mice with Fragile X Syndrome
Musumeci, S. A., Bosco, P., Calabrese, G., Bakker, C., De Sarro, G. B., Elia, M., Ferri, R., & Oostra, B. A. (2000) · Epilepsia · doi:10.1111/j.1528-1157.2000.tb01499.x · Cited by 289
Self-citationFragile X mental retardation protein is associated with translating polyribosomes in neuronal cells
Stefani, G., Fraser, C. E., Darnell, J. C., & Darnell, R. B. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.2306-04.2004 · Cited by 274
Siomi, M. C., Zhang, Y., Siomi, H., & Dreyfuss, G. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.7.3825 · Cited by 271
Irwin, S. A., Idupulapati, M., Gilbert, M. E., Harris, J. B., Chakravarti, A. B., Rogers, E. J., Crisostomo, R. A., Larsen, B. P., Mehta, A., Alcantara, C. J., et al. (2002) · American Journal of Medical Genetics · doi:10.1002/ajmg.10500 · Cited by 270 · cited 2×
“and Segal, 2000], while others could not confirm that phenotype [Irwin et al., 2002; Grossman et al., 2006].”
BackgroundSelf-citationHenderson, C., Wijetunge, L., Kinoshita, M. N., Shumway, M., Hammond, R. S., Postma, F. R., Brynczka, C., Rush, R., Thomas, A., Paylor, R., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004218 · Cited by 249
Metabotropic Glutamate Receptor-Mediated Long-Term Depression: Molecular Mechanisms
Gladding, C. M., Fitzjohn, S. M., & Molnár, E. (2009) · Pharmacological Reviews · doi:10.1124/pr.109.001735 · Cited by 233 · cited 1×
“Specifically, activation of mGluR by applying dihydroxyphenylglycine (DHPG) induces a synaptic plasticity state called long-term depression (LTD) (DHPG-induced LTD) [Massey and Bashir, 2007] which involves several synaptic events including mRNA targeting, and local protein synthesis and degradation [Gladding et al., 2…”
MethodGalvez, R., & Greenough, W. T. (2005) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.30709 · Cited by 231
Osterweil, E. K., Chuang, S.-C., Chubykin, A. A., Sidorov, M., Bianchi, R., Wong, R. K. S., & Bear, M. F. (2013) · Neuron · doi:10.1016/j.neuron.2012.01.034 · Cited by 230
Narayanan, U., Nalavadi, V., Nakamoto, M., Pallas, D. C., Ceman, S., Bassell, G. J., & Warren, S. T. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2969-07.2007 · Cited by 228 · cited 1×
“The activation of mTOR pathway, through protein phosphatase 2A (PP2A) and ribosomal protein S6 kinase (S6K) activation, seems to be involved in the dephosphorylation and phosphorylation of FMRP at different time points during LTD stimulation [Narayanan et al., 2007].”
BackgroundOpen-label add-on treatment trial of minocycline in fragile X syndrome.
Paribello, C., Tao, L., Folino, A., Berry-Kravis, E., Tranfaglia, M., Ethell, I. M., & Ethell, D. W. (2010) · BMC Neurology · doi:10.1186/1471-2377-10-91 · Cited by 223
Behavioral and neuroanatomical characterization of the Fmr1 knockout mouse
Mineur, Y. S., Sluyter, F., de Wit, S., Oostra, B. A., & Crusio, W. E. (2002) · Hippocampus · doi:10.1002/hipo.10005 · Cited by 216 · cited 2×
“, 2008], to decreased social interest [Mineur et al., 2002].”
BackgroundSittler, A., Devys, D., Weber, C., & Mandel, J.-L. (1996) · Human Molecular Genetics · doi:10.1093/hmg/5.1.95 · Cited by 198
Dendritic spine abnormalities in the occipital cortex of C57BL/6Fmr1 knockout mice
McKinney, B. C., Grossman, A. W., Elisseou, N. M., & Greenough, W. T. (2005) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.30183 · Cited by 184 · cited 2×
“cortex or hippocampus of Fmr1 KO adult mice [Galvez and Greenough, 2005;McKinney et al., 2005], or adecreasedone [Braun”
BackgroundGenetic-background modulation of core and variable autistic-like symptoms in Fmr1 knock-out mice
Pietropaolo, S., Guilleminot, A., Martin, B., D'Amato, F. R., & Crusio, W. E. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017073 · Cited by 178 · cited 1×
“Repetitive behavior has been found in Fmr1KOmice too, either as an increased marble burying [Spencer et al., 2011] or as an increased grooming behavior [Pietropaolo et al., 2011].”
BackgroundKhandjian, E. W., Huot, M.-E., Tremblay, S., Davidovic, L., Mazroui, R., & Bardoni, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405398101 · Cited by 178
Expansion of an FMR1 Grey-Zone Allele to a Full Mutation in Two Generations
Fernandez-Carvajal, I., Lopez Posadas, B., Pan, R., Raske, C., Hagerman, P. J., & Tassone, F. (2009) · The Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2009.080174 · Cited by 164
Chen, L., Yun, S.-W., Seto, J., Liu, W., & Toth, M. (2003) · Neuroscience · doi:10.1016/s0306-4522(03)00406-8 · Cited by 160 · cited 1×
“Last but not least, over the last 10 years, a plethora of putative FMRP targetsmRNAshave been identified inneuronal [Brownet al., 2001; Chen et al., 2003; Miyashiro et al., 2003; Zalfa et al., 2003, 2007; Muddashetty et al., 2007; Darnell et al., 2011] (Fig.”
BackgroundPacey, L. K. K., Heximer, S. P., & Hampson, D. R. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.056127 · Cited by 133
Rotschafer, S. E., Trujillo, M. S., Dansie, L. E., Ethell, I. M., & Razak, K. A. (2012) · Brain Research · doi:10.1016/j.brainres.2011.12.041 · Cited by 130
De Rubeis, S., & Bagni, C. (2010) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2009.09.013 · Cited by 126
Self-citationLindemann, L., Jaeschke, G., Michalon, A., Vieira, E., Honer, M., Spooren, W., Porter, R., Hartung, T., Kolczewski, S., Büttelmann, B., et al. (2011) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.185660 · Cited by 118 · cited 1×
“…RO4917523, CTEP) has been shown to reverse phenotypic characteristics, including audiogenic seizures, altered prepulse inhibition (PPI), and open field hyperactivity [Chuang et al., 2005; Yan et al., 2005; De Vrij et al., 2008; Lindemann et al., 2011; Michalon et al., 2012; Pop et al., 2013b].”
BackgroundUtari, A., Chonchaiya, W., Rivera, S. M., Schneider, A., Hagerman, R. J., Faradz, S. M. H., Ethell, I. M., & Nguyen, D. V. (2010) · American Journal on Intellectual and Developmental Disabilities · doi:10.1352/1944-7558-115.5.433 · Cited by 105
Torrioli, M. G., Vernacotola, S., Peruzzi, L., Tabolacci, E., Mila, M., Militerni, R., Musumeci, S., Ramos, F. J., Frontera, M., Sorge, G., et al. (2008) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.32268 · Cited by 100
Chronic administration of AFQ056/Mavoglurant restores social behaviour in Fmr1 knockout mice
Gantois, I., Pop, A. S., de Esch, C. E. F., Buijsen, R. A. M., Pooters, T., Gomez-Mancilla, B., Gasparini, F., Oostra, B. A., D’Hooge, R., & Willemsen, R. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.10.059 · Cited by 100
Self-citationRescue of dendritic spine phenotype in Fmr1 KO mice with the mGluR5 antagonist AFQ056/Mavoglurant
Pop, A. S., Levenga, J., de Esch, C. E. F., Buijsen, R. A. M., Nieuwenhuizen, I. M., Li, T., Isaacs, A., Gasparini, F., Oostra, B. A., & Willemsen, R. (2014) · Psychopharmacology · doi:10.1007/s00213-012-2947-y · Cited by 93
Self-citationAltered maturation of the primary somatosensory cortex in a mouse model of fragile X syndrome
Till, S. M., Wijetunge, L. S., Seidel, V. G., Harlow, E., Wright, A. K., Bagni, C., Contractor, A., Gillingwater, T. H., & Kind, P. C. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds030 · Cited by 91 · cited 1×
“These results suggest that inaccurate timing of developmental processes caused by the loss of FMRP may lead to alterations in neural circuitry that underlie behavioral and cognitive dysfunctions associated with FXS [Till et al., 2012].”
BackgroundSelf-citationPhosphorylation of FMRP inhibits association with Dicer
Cheever, A., & Ceman, S. (2009) · RNA · doi:10.1261/rna.1500809 · Cited by 81
Treatment with valproic acid ameliorates ADHD symptoms in fragile X syndrome boys
Torrioli, M., Vernacotola, S., Setini, C., Bevilacqua, F., Martinelli, D., Snape, M., Hutchison, J. A., Di Raimo, F. R., Tabolacci, E., & Neri, G. (2010) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.33484 · Cited by 71 · cited 1×
“, 2008], while valproic acid appears to ameliorate ADHD symptoms [Torrioli et al., 2010].”
BackgroundMusumeci, S. A., Calabrese, G., Bonaccorso, C. M., D'Antoni, S., Brouwer, J. R., Bakker, C. E., Elia, M., Ferri, R., Nelson, D. L., Oostra, B. A., et al. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2006.08.007 · Cited by 70
Self-citationThe targeting and functions of miRNA-383 are mediated by FMRP during spermatogenesis
Tian, H., Cao, Y.-X., Zhang, X.-S., Liao, W.-P., Yi, Y.-H., Lian, J., Liu, L., Huang, H.-L., Liu, W.-J., Yin, M.-M., et al. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.138 · Cited by 61
De Rubeis, S., Fernández, E., Buzzi, A., Di Marino, D., & Bagni, C. (2012) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-7091-0932-8_23 · Cited by 48
Self-citation
Cited by
Disruption of RNA Metabolism in Neurological Diseases and Emerging Therapeutic Interventions
Nussbacher, J. K., Tabet, R., Yeo, G. W., & Lagier-Tourenne, C. (2019) · Neuron · doi:10.1016/j.neuron.2019.03.014 · Cited by 272
Social deficits in IRSp53 mutant mice improved by NMDAR and mGluR5 suppression
Chung, W., Choi, S. Y., Lee, E., Park, H., Kang, J., Park, H., Choi, Y., Lee, D., Park, S.-G., Kim, R., et al. (2015) · Nature Neuroscience · doi:10.1038/nn.3927 · Cited by 163
Cheng, C., Lau, S. K. M., & Doering, L. C. (2016) · Molecular Brain · doi:10.1186/s13041-016-0256-9 · Cited by 84
Brand, B. A., Blesson, A. E., & Smith-Hicks, C. L. (2021) · Brain Sciences · doi:10.3390/brainsci11070904 · Cited by 39
Persistent astrocyte activation in the fragile X mouse cerebellum
Pacey, L. K. K., Guan, S., Tharmalingam, S., Thomsen, C., & Hampson, D. R. (2015) · Brain and Behavior · doi:10.1002/brb3.400 · Cited by 39
Metadata
- Authors
- Bagni, C., & Oostra, B. A.
- Venue
- American Journal of Medical Genetics Part A
- Publisher
- Wiley
- Published
- 2013-09-24
- Volume
- 161
- Issue
- 11
- Pages
- 2809-2821
- ISSN
- 1552-4825 (ISSN-L)
- 1552-4833
- OpenAlex
- W2094192094
- Cited by
- 103
- References
- 78
- FWCI
- 8.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.